Alzheimer’s Disease has been identified as proteopathic disease, caused by accumulation of abnormally folded A-beta, tau proteins in brain. As per Alzheimer’s association, it is estimated that over 65 years and above age group one per person suffering in every eight from this devastating neurodegenerative disorder and may reach to 60 million by 2050 worldwide. The treatment of AD patient is also economically cost effective; nearly 80-100 billion dollars are spending AD health care in US only. It would be a great achievement that if any ideal compounds extracted from natural sources as potential therapeutics for Alzheimer’s treatment Disease with low cost. In the present study an attempt was made to evaluate the Emblica officinalis fruit Methanolic (EoFM) extract effect on Alzheimer’s Disease induced rats. The results of invivo studies against cholinergic neurotransmitters viz., ACh and AChE revealed that EoFM extract exerted anti-cholinesterase properties in AD-induced rats. The inslico results it was evident that bioactive compounds extracted from the Emblica officinalis showed ability to inhibit Human AChE (PDB ID: 4PQE). Among the selected compounds, Ellagic acid (PI: 5281855), Lonicerin (PI: 5282152) and Phyllanemblinin-A (PI: 11135859) have effective AChE enzyme inhibitory activity. Finally, it may conclude that EoFM extract has potential neuroprtective activity to enhance cholinergic cognitive dysfunctions in Alzheimer‘s.